Bausch Health Companies (BHC) Asset Utilization Ratio (2010 - 2026)
Bausch Health Companies (BHC) reported Asset Utilization Ratio of 0.41 for Q1 2026, up 12.65% on a YoY basis from 0.37 in Q1 2025, and up 7.27% sequentially from 0.39 in Q4 2025.
Bausch Health Companies (BHC) Asset Utilization Ratio (2010 - 2026) Analysis & Trends
Bausch Health Companies (BHC) has 17 years of Asset Utilization Ratio data on file, last reported at 0.41 in Q1 2026.
- For the quarter ending Q1 2026, Asset Utilization Ratio rose 12.65% year-over-year to 0.41; the trailing twelve-month figure through Mar 2026 stood at 0.41 (up 12.65% YoY), and the FY2025 full-year result was 0.39, up 8.64% from the prior year.
- Asset Utilization Ratio climbed to 0.41 in Q1 2026, from 0.39 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.48 in Q3 2022 to a low of 0.31 in Q4 2022.
- A 5-year average of 0.37 and a median of 0.36 in 2024 frame the typical range for Asset Utilization Ratio.
- Across the five-year window, Asset Utilization Ratio jumped 75.09% in 2022 and tumbled 32.8% in 2023, its largest moves.
- Tracing BHC's Asset Utilization Ratio over 5 years: stood at 0.31 in 2022, then climbed by 2.98% to 0.32 in 2023, then advanced by 12.71% to 0.36 in 2024, then gained by 6.41% to 0.39 in 2025, then climbed by 7.27% to 0.41 in 2026.
- Business Quant data shows BHC's Asset Utilization Ratio at 0.41 in Q1 2026, 0.39 in Q4 2025, and 0.37 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 0.43 |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 0.62 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 0.46 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.43 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.39 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 0.65 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 0.37 |
| 10 | Bausch Health Companies | 1.66 Bn | 1.33 Bn | 2.52 Bn | 0.41 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.41 |
| Dec 31, 2025 | 0.39 |
| Sep 30, 2025 | 0.37 |
| Jun 30, 2025 | 0.37 |
| Mar 31, 2025 | 0.37 |
| Dec 31, 2024 | 0.36 |
| Sep 30, 2024 | 0.36 |
| Jun 30, 2024 | 0.34 |
| Mar 31, 2024 | 0.33 |
| Dec 31, 2023 | 0.32 |
| Sep 30, 2023 | 0.32 |
| Jun 30, 2023 | 0.33 |
| Mar 31, 2023 | 0.32 |
| Dec 31, 2022 | 0.31 |
| Sep 30, 2022 | 0.48 |
| Jun 30, 2022 | 0.46 |
| Mar 31, 2022 | 0.46 |
| Dec 31, 2021 | 0.46 |
| Sep 30, 2021 | 0.29 |
| Jun 30, 2021 | 0.28 |